Swiss Pharmaceutical Exports to Russia Remain Stable Despite Conflict

Three and a half years after Moscow launched its assault on Ukraine, the flow of Swiss medicine into the Russian Federation remains not just active, but defiantly stable. In a staggering display of economic resilience, the Swiss pharmaceutical industry supplied Russia with goods valued at CHF 1.8 billion in 2024 alone. This figure essentially mirrors pre-pandemic trade levels from 2019, proving that for Big Pharma, the war has done little to disrupt the supply chain.

While other sectors have fled or been forced out by sanctions, pharmaceuticals have consolidated their dominance. Today, these products account for a massive 80% of all Swiss exports to Russia—a dramatic surge from the 50% share recorded before the conflict began in February 2022. As 2025 unfolds, the sector is on track to match last year's numbers, cementing a trade relationship that persists in the shadow of geopolitical turmoil. While Russia represents less than 2% of Switzerland's total global pharma exports, the sheer volume of goods flowing East underscores a critical, and controversial, economic lifeline.

Titans of the industry, including Novartis and Roche, stand firm behind a shield of humanitarian responsibility. Their defense is simple and legally sound: international law and Swiss sanctions explicitly exempt medical and humanitarian goods. "Novartis is committed to ensuring access to medicines for people all over the world, regardless of where they are," the company declared, framing their continued presence as a moral imperative rather than a commercial choice.

The industry argues that severing this lifeline would not punish the Kremlin, but rather the ordinary Russian citizens dependent on essential preparations. Disruption, they warn, could have catastrophic consequences for patient health. This stance allows Swiss giants to navigate the complex moral landscape of the war, maintaining a steady flow of revenue while claiming the moral high ground of medical neutrality. However, as the war drags on, this "humanitarian shield" is facing increasingly heavy fire from observers who see it as a convenient cover for profit.

Public Eye, the relentless Swiss watchdog, is tearing down the industry's defense. Oliver Classen, a spokesperson for the NGO, slammed the continued trade, telling the Awp news agency that "Swiss pharmaceutical companies should also withdraw from Russia." The organization rejects the narrative that Swiss drugs are the only option for Russian patients, asserting that "there are sufficient alternatives" for the indispensable drugs supplied by Roche and Novartis.

The criticism extends beyond simple exports. Public Eye has labeled the discontinuation of clinical trials—while still selling products—as unethical, arguing that if companies stay, they should only supply products necessary for research. The NGO contends that the industry is hiding behind the "essential medicine" label to maintain market share in a pariah state. For these critics, the continued volume of trade is not a humanitarian mission, but a failure of corporate moral courage.

While the export numbers remain high, the operational footprint of Swiss pharma in Russia is shrinking. Roche admits its activities have been "significantly restricted," confirming that new clinical trials have been suspended and no new patients are being admitted to existing studies. The company emphasizes that while it adheres to international law to supply essential drugs, it is not business as usual. Russia now accounts for roughly 1% of Roche’s turnover, a figure that minimizes financial risk while maintaining a market presence.

Sandoz and Lonza are treading similar paths. Sandoz highlights that about half of its products in Russia appear on the World Health Organization’s list of essential medicines, reinforcing the humanitarian argument. Lonza, meanwhile, claims a "very limited" relationship, citing a lack of plants or offices within the Federation. These strategic restrictions allow the companies to walk a tightrope: keeping the supply lines open for revenue and reputation, while technically freezing growth and investment to appease Western sensibilities.

Ultimately, the debate boils down to the message Switzerland sends to the world. Public Eye concedes that based on turnover and market share, Swiss pharma companies are likely not directly financing Putin’s war machine. However, Classen argues that a full withdrawal would send an "important political signal to the Russian government." By staying, Swiss companies normalize trade relations with an aggressor state, potentially undermining the diplomatic isolation the West seeks to impose.

As 2025 progresses with export figures holding steady, Switzerland remains in a precarious position. The country is balancing its traditional stance of neutrality and humanitarian aid against the urgent demand for a unified Western front. With the pharmaceutical sector now constituting the overwhelming majority of Swiss trade with Russia, the industry is no longer just a business player—it is the primary diplomatic bridge between Bern and Moscow, for better or for worse.